Look at the chart last 6 weeks or so, two steps forward, one step back. Uptrend nicely intact.
Oppenheimer's coverage will hopefully attract other heavyweight analysts to have a look at this, just in case they are missing something. Until Oppenheimer, I don't think analyst coverage was taken seriously. Doesn't look like Opp's coverage helped much either, but they are respected. If another chimes in with similar sentiments, it'll run hard. This is really a case of waiting. The product is solid and a serious step up on current standard of care unless I am missing something. Odds of rejection by the FDA are nominal, it's a formality, albeit a painfully long one. My only concern at this level is a general market crash while we wait, which will take everything with it. If Oppenheimer is right, Master I 12-month results will hopefully drive some meaningful sales in jurisdictions where MGuard Stent is already approved. There certainly are an impressive group of physicians standing behind this, and the recent hire proves they are ready to pursue a more aggressive sales strategy. GL.
Absolutely correct. The bloody markets are still slowing it down, but the fact that it continues its uptrend regardless is confirmation in the extreme that this is news (potential buyout or partnership) or recovery driven, a Dendreon recovery with more and physicians and patients opting for the future.
Oppenheimer is by far the most reputable coverage NSPR Has received to date. Maxim, Cowen, Benchmark, Chardran, etc, all fine, but renowned for their speculative (ie, gambling) nature. Oppenheimer doesn't fit into that niche, they are the real deal. I think Oppenheimer's coverage is a significant development, and their language (see original post) is pretty aggressive. "Disruptive technology" is not a term used loosely by a respectable analyst. Certainly hasn't been a couple of inspiring days, but this is an extremely low volume trader that is easily moved up or down. Patience will prove the investor's most valuable asset here.
"..potentially disruptive technology..." "..potential upside to our model..."
In the report, Oppenheimer noted, “We are initiating coverage of InspireMD, Inc. with an Outperform rating and $6 price target. We view InspireMD's proprietary, CE Mark approved MGuard Embolic Protection Stent (EPS) as a novel and potentially disruptive technology for the treatment of ST Elevation Myocardial Infarction (severe heart attacks, or STEMI). MGuard's US pivotal trial is currently enrolling and we anticipate FDA approval in late 2016. In the interim, we look for recently presented positive 12-month follow-up data from the randomized MASTER trial to drive meaningful sales growth internationally. Key pipeline opportunities such as MGuard Carotid and drug-eluting MGuard represent potential upside to our model.”
NSPR is decidedly unsexy, but dude is right. This is one of those you lock away. You will sell if you keep looking, and wondering about missed opportunities elsewhere. Hope I can follow my own advice.
Appropriate since the plunge happened the other way around.
No, not possible. If there is any material news, they have to release at earliest convenience, can't wait for an event like this. But it's time analysts take another look at Dendreon after the hate fest. No more money to be made on the short side anyway.
..that the market finally lost its marbles. I could be wrong, but I don't think we'll be seeing a Santa Clause rally this year.
I have him on ignore now, maybe he'll lose interest eventually and stop annoying people. You're free to go on ad nauseum about the looming, inevitable short squeeze Havenger. Anyway, please leave me alone, it's embarrassing, you win.
Yes, my posts are classic P&D, just look at the original post on this thread, pumping to high heaven!
My apologies to the NSPR board for this idiot following me here. Havenger, I now have you on ignore, so there is no point in further stalking. Please leave me alone and stop annoying people. Get help.
Seriously, leave me alone. Discuss DNDN on this board, don't take it elsewhere. Invest in a little dignity with all the DNDN profits from the looming mother of all short squeezes.
Legendary? Not today I guess, but he does seem to have an exceptional track record, especially for a guy with a psychology degree alone, or perhaps because of it.
I never said there would not be a squeeze, just not to count on one you idiot! That's sound advice. Do not invest on dreams of a VW scenario, that's what you are pushing and you have been doing so since many dollars ago. You are an idiot, it's just too bad that should DNDN recover, you will be profiting from it. Anybody who has jumped aboard your ship of fools prior to a couple of weeks ago is deep in the red. What's worse, they just don't understand why.
Asher selling may not be indicative of anything except his needing the money, and it's encouraging to see they were scooped up at almost neutral market prices, but trying to spin this into an actual positive is beyond reasonable. Another possibility, albeit a tad dark, is that he may be helping the relatively new short position of 500K cover - volumes match.
You're a fool Havenger. That's what fools do - they repeat the same stupid story over and over again, to anyone who will listen, and there will always be someone unfortunately. Stop misleading people. There is nobody on this board, or any other that I can find, that has been more consistently wrong than you.
Shorts are vultures, but vultures have a way of knowing when something is doomed. It's nice to see they are not circling over NSPR. This would have been a good time for them to pile on if they saw a bleak future here. That doesn't mean success is assured, but it's something.